340B HIV Providers Warn of “Drug Industry Disinformation Campaign”

Drug manufacturers’ true goal is to cripple the 340B program, says Shannon Stephenson, RWC-340B President and CEO of Cempa Community Cares.

Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program.

Please Login or Become a Paid Subscriber

Read More »

PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism

Headline from recent blog post by PhRMA spokesperson Nicole Longo.

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

Read More »

340B Report Exclusive: GAO Is Asking Hospitals if They Share 340B Savings with Low-Income Uninsured Patients at Contract Pharmacies

GAO
The GAO is asking 340B hospitals that applied to get their eligibility restored if they give low-income uninsured patients a break on drug prices at their contract and in-house pharmacies.

A federal watchdog agency wants to know if 340B hospitals give low-income uninsured patients a break on drug prices at their contract and in-house pharmacies as part of the agency’s evaluation of a law that helps some hospitals

Read More »

Health Policy Think Tank Commonwealth Fund Issues 340B Primer

Commonwealth Fund
The Commonwealth Fund has issued a primer that explores how 340B program growth has spawned controversy over the drug discount program.

The Commonwealth Fund published a primer on the 340B program last week highlighting the program’s growth and the controversy its growth has sparked.

Please Login or Become a Paid Subscriber to View this Content

Read More »

In Violation of ‘Spirit’ of Anti-Kickback Law, Drug Manufacturer Donations to Patient Assistance Charities Result in Bigger Profits, Study Finds

Health Affairs
Drug manufacturers' donations to patient assistance charities effectively subsidize the purchase of their own drugs, a new study published in Health Affairs concludes. PhRMA counters that coupons and other forms of assistance help patients afford their out-of-pocket costs.

In a new study published in Health Affairs, researchers find that drug manufacturers are likely to profit from donations they make to patient assistance charities that help patients cover out-of-pocket costs associated with expensive treatments for serious and often rare

Read More »

Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds

Hospital, outpatient, Medicare, prescription drug
80% of hospitals in Medicare’s outpatient prospective payment system would see their net payments decline next year if CMS ends a nearly 30% cut in 340B hospitals’ drug payments, according to a private oncologist group funded study.

Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began

Read More »

Financial Outlook Deteriorating for Nonprofit Hospitals in 2022 and Beyond, Credit Rating Agency Says

Mass General Brigham is among the nonprofit health systems that have reported significant financial pressure this year.

Fitch Ratings predicts a “deteriorating” outlook for nonprofit hospitals and health systems through the remainder of 2022 and into 2023.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Medicare and Hep C Patients Would Save Over $100 Million if Plan Sponsors Adopted Generic Use, OIG Finds

The HHS Inspector General says Part D beneficiaries are far less likely than Medicaid beneficiaries to use lower-cost authorized generic versions of HCV drugs Epclusa (pictured above) and Harvoni.

Medicare Part D beneficiaries were much less likely to use lower-cost, authorized generic versions of highly expensive hepatitis C drugs Harvoni and Epclusa in 2019 and 2020 than Medicaid beneficiaries, driving up costs for Part D enrollees and

Read More »

Federal Data Show 340B Sales Hit $43.9 Billion in 2021, Drug Industry Consultant Reports

DSH hospitals accounted for 78.1% of all 340B program purchases in 2021, according to federal data obtained by Drug Channels Institute under the Freedom of Information Act.

Total sales in the 340B drug pricing program reached $43.9 billion in 2021, a 15.6% increase over 2020 sales and more than 3.5 times above total sales in 2015 ($12.1 billion), according to federal data obtained by Drug

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report